AnteoTech (ASX: ADO) has completed a $3.5 million capital raising through a share placement to institutional, sophisticated and professional investors. The placement was scaled back due to strong investor demand, signalling market confidence in the company’s dual commercialisation strategy across Life Sciences and Advanced Battery Technologies. The raise positions AnteoTech with a pro-forma cash balance of $6.6 million (as of 30 September 2025) to convert existing customer trials into commercial supply agreements.
The placement priced shares at $0.0155 (1.55 cents), representing a 20.8% discount to the 30-day volume weighted average price. A total of 245.7 million new shares were issued, with participants receiving free attaching options: one Listed Option and one Unlisted Option for every two shares issued. Listed Options are exercisable at $0.035 (3.5 cents) and expire 31 May 2026, while Unlisted Options carry the same exercise price but expire 31 January 2028.
Where the funds will go
The capital allocation prioritises revenue-generating activities, with sales and business development receiving the largest share of funding.
| Use of Funds Category | Allocation | % of Total | Strategic Purpose |
|---|---|---|---|
| Sales and Business Development | $1.4M | 40% | Customer acquisition and conversion of trial programs to commercial agreements |
| Strategic Partnerships | $350K | 10% | Acceleration of partnership discussions in EV, drone and wearable battery segments |
| Materials for product sales & development | $350K | 10% | Support initial commercial supply and qualification programs |
| Technical product development | $525K | 15% | Enhancement of existing product lines |
| R&D – new products | $175K | 5% | Development of new applications and markets |
| Working Capital | $700K | 20% | General corporate and operational expenses |
The capital allocation structure reflects AnteoTech’s shift toward commercialisation, with 40% of funds directed to sales and business development activities. Strategic partnerships and product materials each receive $350,000, supporting near-term revenue conversion targets.
Join thousands of readers who start here
Our best articles, sent straight to your inbox. You can unsubscribe anytime.
Near-term commercial targets for 2H FY26
AnteoTech has outlined concrete milestones for the second half of FY26 that investors can monitor to track commercial progress:
- Conversion of Advanced Battery Technology and Life Sciences customer trials to initial commercial supply agreements, including for new product Anteo S
- Trialling and initial commercial supply into the US market of the joint product developed with Black Diamond Structures (announced 25 September 2025)
- Progression of strategic partnership discussions in drone, wearable and EV battery segments
- New Life Sciences customer conversions in India through the Serum Institute of India relationship
- New diagnostic product development and market entry commercial agreements in CLIA and ELISA markets
The company aims to secure new sales and partnerships globally during calendar year 2026, supported by two recently hired sales personnel who expand the company’s commercialisation capability.
Advanced Battery Technologies momentum
AnteoTech’s Ultranode X™ technology has achieved a significant technical milestone of more than 1,000 cycles at 80% capacity retention, as reported in November 2025. The achievement validates the product’s potential for electric vehicle applications and positions the company for ongoing strategic partnership discussions in the EV sector.
The company is progressing sales conversion initiatives for Anteo S, a new product designed for use in ceramic-coated lithium-ion battery separators. Management has stated these initiatives target the growing market for high-performance battery components in e-mobility, wearables and consumer applications.
Life Sciences expansion in India and new markets
The Life Sciences division is expanding its AnteoBind NXT™ product into lateral flow and Luminex In Vitro Diagnostics markets globally, with particular focus on India. The relationship with Serum Institute of India represents a key growth driver, with AnteoTech aiming to secure additional similar customers in the region.
The company is entering new IVD market segments through Chemiluminescence Immunoassays (CLIA) and Enzyme-Linked Immunosorbent Assay (ELISA) technologies. These expansions will occur through joint product development and market entry commercial agreements, providing scalable revenue pathways without requiring significant upfront capital investment.
What is surface chemistry and why does it matter for batteries and diagnostics?
AnteoTech’s core technology is a binding chemistry platform that improves how materials stick to surfaces at a molecular level. This platform creates competitive advantages across two distinct markets: batteries and medical diagnostics.
In battery applications, the company’s surface coatings allow battery materials to bond more effectively, resulting in higher energy density and longer cycle life. For lithium-ion batteries using high silicon anodes, the coating technology helps prevent degradation that typically occurs during charge and discharge cycles.
In diagnostic testing, the AnteoBind technology improves how test components attach to surfaces within diagnostic devices. This creates more sensitive and reproducible test results, particularly important for point-of-care testing where reliability and speed are critical. The technology enables faster, more accurate test results in settings where laboratory testing is impractical.
The commercial benefit of this platform approach is that AnteoTech can leverage the same core chemistry across multiple end markets, each with distinct customer bases and revenue opportunities.
Management perspective on the raise
“I would like to thank existing shareholders who supported the Company in this capital raise and welcome new shareholders to the Company. AnteoTech is entering a highly focused commercial phase across both Life Sciences and Advanced Battery Technologies. Following the achievement of recent technical and product development milestones, this funding provides the capacity to accelerate sales initiatives and progress strategic discussions by supporting qualification and engagement programs, leading to the securing of new sales and partnerships globally in CY2026.”
Merrill Gray, Managing Director & Chief Executive Officer
Management has expanded sales capability with two new personnel joining the business as part of the company’s June 2025 strategy, which focuses on revenue growth, geographic expansion driven by market demand, and continued cost discipline. The strategy targets specific jurisdictions including India, USA, South Korea, Japan and Europe through a combination of direct sales, distributor relationships and support from Austrade and Trade & Investment Queensland.
Enjoyed this article?
We publish high-impact stories like this a few times a week. No spam.
Placement details at a glance
The key terms of the $3.5 million capital raising are as follows:
- 245.7 million shares issued at $0.0155 (1.55 cents per share)
- Discount levels: 20.8% to 30-day VWAP, 24.6% to 15-day VWAP, 26.2% to last traded price
- Free attaching options: 1 Listed Option + 1 Unlisted Option per 2 shares issued
- Listed Options exercise price: $0.035 (3.5 cents), expiry 31 May 2026
- Unlisted Options exercise price: $0.035 (3.5 cents), expiry 31 January 2028
- Settlement date: 2 February 2026
- Expected ASX quotation: 3 February 2026
The option structure provides potential upside for placement participants if the share price appreciates toward the 3.5 cent exercise price. Both classes of options carry the same exercise price, with the Unlisted Options providing a longer timeframe extending to January 2028.
MST Financial Services Pty Ltd and Alpine Capital Pty Ltd acted as Joint Lead Managers for the placement, receiving a combined 6% fee plus broker options split equally between Listed and Unlisted classes.
Want more Biotech news like this?
AnteoTech’s capital raise reflects the type of commercial inflection point that defines success in the Biotech and Healthcare sectors. For investors tracking non-resource ASX opportunities, missing these developments can mean missing the opportunity entirely. StockWire X delivers FREE breaking news alerts and comprehensive analysis across Tech, Biotech, Healthcare, Finance and Industrials—covering the sectors that drive growth beyond the mining cycle.
Over 20,000+ active subscribers rely on the Big News Blasts service to stay ahead of capital raises, clinical milestones, commercialisation updates and partnership announcements. To receive these alerts directly, click the “Free Alerts” button in the menu at StockWire X and join Australia’s largest community of non-resource investors.